FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD

The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news